Articles tagged “compounding”
13 articles
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
The FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 to evaluate 7 peptide compounds for 503A inclusion. Here's what they decided and what it means for patients, clinics, and the compounding industry.
Compounding Pharmacy Red Flags: How to Spot a Bad Actor
Not all compounding pharmacies are created equal. With the FDA issuing warning letters and the PCAC meeting approaching, here's how to identify legitimate pharmacies — and avoid dangerous ones.
The Economics of Peptide Therapy: Why It Costs What It Costs
Peptide therapy costs range from $50/month to $2,000+. Here's what drives the price — from raw material sourcing to pharmacy markup — and how to evaluate whether you're paying a fair price.
What Happens If the FDA Reverses Course on Peptides
The PCAC could vote no. The next administration could reverse the current one's position. Here's what a regulatory reversal would actually mean for patients, clinics, and the compounding industry.
What Hims & Hers Entering Peptides Means for the Market
Hims & Hers acquired a peptide manufacturing facility, their stock surged 48%, and they're building a peptide product line. Here's what this means for patients, clinics, and the competitive landscape.
What Category 2 Removal Actually Means (And What It Doesn't)
The FDA removed 12 peptides from Category 2 in April 2026. Many people think this means they're legal to compound. It doesn't. Here's the critical legal nuance that most sources are getting wrong.
503A vs 503B: What's the Difference Between Compounding Pharmacies?
The terms 503A and 503B come up constantly in peptide therapy discussions, but most patients have no idea what they mean. Here's a clear breakdown of the two types of compounding pharmacies, how they're regulated, and why it matters for your peptide prescription.
What Does Peptide Therapy Actually Cost in 2026?
Peptide therapy pricing is opaque. We compiled real pricing data from 7 telehealth clinics to show what you'll actually pay — from consultation fees to monthly compound costs.
The History of Peptide Regulation: From the 2023 Ban to the 2026 Reversal
How 19 peptides went from legally compoundable to banned to partially restored in three years — a timeline of the most turbulent period in peptide regulatory history.
What Is Pharmaceutical-Grade? Understanding Peptide Quality Standards
The term 'pharmaceutical-grade' gets thrown around constantly in the peptide space. Here's what it actually means, how it differs from research-grade, and why it matters for safety.
The July 2026 PCAC Meeting: What's at Stake for BPC-157, TB-500, Semax, and More
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee will decide whether seven peptides — including BPC-157 and TB-500 — get formally authorized for compounding. Here's what the process looks like, what outcomes are possible, and what it means for patients and clinicians.
FDA Removes 12 Peptides from Category 2: What It Actually Means
On April 15, 2026, the FDA announced that 12 peptides — including BPC-157, TB-500, Semax, and Epitalon — will exit the Category 2 restricted list on April 22. Here's a clear breakdown of what changed, what didn't, and what happens next.
The 2026 FDA Peptide Reclassification: What Changed and What It Means
In February 2026, 14 peptides were reclassified from Category 2 to Category 1. Here's what that means for patients, clinics, and the peptide market.